HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,866 | -100.0% | 101,211 | -62.7% | 0.01% | -68.8% |
| Q3 2022 | $10,740,000 | +53.3% | 271,615 | +70.6% | 0.02% | +60.0% |
| Q2 2022 | $7,005,000 | -58.6% | 159,201 | -61.7% | 0.01% | -52.4% |
| Q3 2021 | $16,929,000 | +916.1% | 416,140 | +556.4% | 0.02% | +600.0% |
| Q3 2020 | $1,666,000 | +397.3% | 63,400 | +407.9% | 0.00% | +200.0% |
| Q2 2020 | $335,000 | -82.1% | 12,484 | -88.0% | 0.00% | -80.0% |
| Q1 2020 | $1,873,000 | -72.6% | 104,097 | -73.0% | 0.01% | -68.8% |
| Q4 2019 | $6,848,000 | +305.7% | 386,241 | +254.9% | 0.02% | +300.0% |
| Q3 2019 | $1,688,000 | +61.2% | 108,846 | +67.3% | 0.00% | +100.0% |
| Q1 2019 | $1,047,000 | -88.9% | 65,055 | -86.5% | 0.00% | -90.9% |
| Q1 2018 | $9,437,000 | +7103.8% | 481,718 | +4622.7% | 0.02% | – |
| Q2 2017 | $131,000 | – | 10,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |